Systemic Anti-Cancer Therapy Regimen Library
LEU ALL BCR-ABL1+ - UKALL60+ with imatinib
Treatment Overview
UKALL60+ with imatinib is intended for older patients who are BCR-ABL1 positive.
This regimen consists of:
- Steroid pre-phase [optional]
- Phase 1 Induction
- Phase 2 Induction
- Consolidation
- Maintenance
Each Cycle/phase starts after count recovery from the previous Cycle/phase with:
- Neutrophils greater than 0.75 x 109/L, and
- Platelets greater than 75 x 109/L.
imatinib is taken continuously, the dose included in regimen below may be increased or decreased based on individual patient response and tolerability.
dexamethasone pre-phase can be given for 5 to 7 days.
Followed by:
Starts after count recovery from Phase 1 Induction.
Starts after count recovery from Phase 2 Induction.
Starts after count recovery from Consolidation.
Supportive Care Factors
| Factor | Value |
|---|---|
| Antifungal prophylaxis: | Variable |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
| Constipation risk: | Variable |
| Diarrhoea risk: | Variable |
| Emetogenicity: | Variable |
| Gastroprotection: | Gastroprotection is recommended |
| Pneumocystis jirovecii pneumonia (PJP) prophylaxis: | Routine antibiotic prophylaxis recommended |
| Tumour lysis syndrome prophylaxis: | Variable |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Gastroprotection: Gastroprotective agents are only intended for short term use while patient is receiving corticosteroid treatment doses
References
Cancer Research UK and University College London UKALL60+(HOVON117 ALL) A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia Clinicaltrials.gov no: NCT01616238 version 3.0 25 May 2015 https://northerncanceralliance.nhs.uk/wp-content/uploads/2019/01/UKALL60-Protocol-v3.0-21.05.2015.pdf (Accessed 21 September 2022).
REX Medical Limited. Imatinib New Zealand Data Sheet 5 June 2020. https://www.medsafe.govt.nz/profs/datasheet/i/imatinibcap.pdf (Accessed 17 October 2020).
Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.